935-P：不同胰岛素治疗的1型糖尿病患者的人格特征和血糖控制

IF 7.5 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes Pub Date : 2025-06-13 DOI:10.2337/db25-935-p

EUGENIA RESMINI, ANGELO V. CORNAGHI, VALENTINA TURRA, EMANUELA ZARRA, ELENA CIMINO, MARCO SANDRI, MATTEO MIGAZZI, GIULIA MASSARI, BERNADETTA PASQUINO, CRISTINA MASCADRI, SARA MADASCHI, ANGELA GIRELLI

{"title":"935-P：不同胰岛素治疗的1型糖尿病患者的人格特征和血糖控制","authors":"EUGENIA RESMINI, ANGELO V. CORNAGHI, VALENTINA TURRA, EMANUELA ZARRA, ELENA CIMINO, MARCO SANDRI, MATTEO MIGAZZI, GIULIA MASSARI, BERNADETTA PASQUINO, CRISTINA MASCADRI, SARA MADASCHI, ANGELA GIRELLI","doi":"10.2337/db25-935-p","DOIUrl":null,"url":null,"abstract":"Introduction and Objective: Glycemic variability is becoming increasingly important in evaluating effectiveness of treatment in patients with type 1 diabetes. Personality traits may impact daily therapeutic decisions, potentially affecting quality of glycemic control. This study aimed to explore potential relationship between personality traits and glycemic control, and to examine differences across various insulin therapies. Methods: Cross-sectional observational study, 130 type 1 diabetic patients (68 females, 62 males, 43.77±12.81 years, BMI 24.95±4.57 kg/m2, disease duration 23.23±12.39 years, HbA1c 7.04±0.92%), divided in three groups: 1. Multiple daily injections (MDI, n=45); 2. Traditional pumps (TP, n=35); 3. Advanced hybrid closed-loop systems (AHCL, n=50). Personality was assessed through the Personality Inventory for DSM-V questionnaire. Kruskal-Wallis test for independent samples was used to compare continuous variables among three groups. Associations between pairs of variables were analyzed using Spearman’s correlation. Results: AHCL group showed higher emotional lability (p=0.042), perseveration (p=0.005), separation insecurity (p=0.007) and distractibility (p=0.021) than MDI and TP group. The pathological trait of emotional lability (above the 75th percentile) was more frequently present in the AHCL (32%, p=0.029) than MDI and TP group. This trait was associated with an increase in TAR&gt;180 (p=0.035) and GMI (p=0.025), a decrease in TBR&lt;70 (p=0.014). However, glycemic control and metrics were significantly better in the AHCL than MDI and TP group (HbA1c, p=0.03; GRI, p&lt;0.001; TIR, p=0.004; TAR&gt;180, p=0.05; TBR&lt;70, p=0.018, TAR&gt;250, p=0.041; CV, p=0.012; SD, p=0.01). Conclusion: AHCL systems may help mitigating the impact of problematic personality traits, that could interfere achieving an optimal glycemic control. Disclosure E. Resmini: None. A.V. Cornaghi: None. V. Turra: None. E. Zarra: None. E. Cimino: Speaker's Bureau; roche, Abbott. M. Sandri: None. M. Migazzi: None. G. Massari: None. B. Pasquino: None. C. Mascadri: None. S. Madaschi: None. A. Girelli: Consultant; Abbott Diagnostics, Sanofi, Roche Diabetes Care.","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"10 1","pages":""},"PeriodicalIF":7.5000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"935-P: Personality Traits and Glycemic Control in Type 1 Diabetic Patients with Different Insulin Therapies\",\"authors\":\"EUGENIA RESMINI, ANGELO V. CORNAGHI, VALENTINA TURRA, EMANUELA ZARRA, ELENA CIMINO, MARCO SANDRI, MATTEO MIGAZZI, GIULIA MASSARI, BERNADETTA PASQUINO, CRISTINA MASCADRI, SARA MADASCHI, ANGELA GIRELLI\",\"doi\":\"10.2337/db25-935-p\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction and Objective: Glycemic variability is becoming increasingly important in evaluating effectiveness of treatment in patients with type 1 diabetes. Personality traits may impact daily therapeutic decisions, potentially affecting quality of glycemic control. This study aimed to explore potential relationship between personality traits and glycemic control, and to examine differences across various insulin therapies. Methods: Cross-sectional observational study, 130 type 1 diabetic patients (68 females, 62 males, 43.77±12.81 years, BMI 24.95±4.57 kg/m2, disease duration 23.23±12.39 years, HbA1c 7.04±0.92%), divided in three groups: 1. Multiple daily injections (MDI, n=45); 2. Traditional pumps (TP, n=35); 3. Advanced hybrid closed-loop systems (AHCL, n=50). Personality was assessed through the Personality Inventory for DSM-V questionnaire. Kruskal-Wallis test for independent samples was used to compare continuous variables among three groups. Associations between pairs of variables were analyzed using Spearman’s correlation. Results: AHCL group showed higher emotional lability (p=0.042), perseveration (p=0.005), separation insecurity (p=0.007) and distractibility (p=0.021) than MDI and TP group. The pathological trait of emotional lability (above the 75th percentile) was more frequently present in the AHCL (32%, p=0.029) than MDI and TP group. This trait was associated with an increase in TAR&gt;180 (p=0.035) and GMI (p=0.025), a decrease in TBR&lt;70 (p=0.014). However, glycemic control and metrics were significantly better in the AHCL than MDI and TP group (HbA1c, p=0.03; GRI, p&lt;0.001; TIR, p=0.004; TAR&gt;180, p=0.05; TBR&lt;70, p=0.018, TAR&gt;250, p=0.041; CV, p=0.012; SD, p=0.01). Conclusion: AHCL systems may help mitigating the impact of problematic personality traits, that could interfere achieving an optimal glycemic control. Disclosure E. Resmini: None. A.V. Cornaghi: None. V. Turra: None. E. Zarra: None. E. Cimino: Speaker's Bureau; roche, Abbott. M. Sandri: None. M. Migazzi: None. G. Massari: None. B. Pasquino: None. C. Mascadri: None. S. Madaschi: None. A. Girelli: Consultant; Abbott Diagnostics, Sanofi, Roche Diabetes Care.\",\"PeriodicalId\":11376,\"journal\":{\"name\":\"Diabetes\",\"volume\":\"10 1\",\"pages\":\"\"},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2337/db25-935-p\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db25-935-p","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

简介和目的：血糖变异性在评估1型糖尿病患者治疗效果方面变得越来越重要。人格特征可能会影响日常治疗决策，潜在地影响血糖控制的质量。本研究旨在探索人格特征与血糖控制之间的潜在关系，并检查不同胰岛素治疗方法的差异。方法：对130例1型糖尿病患者进行横断面观察研究，其中女性68例，男性62例，43.77±12.81岁，BMI 24.95±4.57 kg/m2，病程23.23±12.39年，HbA1c 7.04±0.92%，分为三组：1。每日多次注射（MDI, n=45）；2. 传统泵（TP, n=35）；3. 先进混合闭环系统（AHCL, n=50）。通过DSM-V人格量表进行人格评估。采用独立样本的Kruskal-Wallis检验比较三组间的连续变量。使用Spearman相关分析变量对之间的关联。结果：AHCL组情绪不稳定性（p=0.042）、坚持性（p=0.005）、分离不安全感（p=0.007）、分心性（p=0.021）高于MDI组和TP组。与MDI和TP组相比，AHCL组出现情绪不稳定（75百分位以上）的病理特征较多（32%,p=0.029）。该性状与TAR&；gt;180 （p=0.035）和GMI （p=0.025）增加，TBR& gt; 70 （p=0.014）减少相关。然而，AHCL组的血糖控制和指标明显优于MDI组和TP组(HbA1c, p=0.03；GRI, p&肝移植;0.001;行动,p = 0.004;TAR& gt; 180, p = 0.05;TBR<70, p=0.018, TBR& gt;250, p=0.041；简历,p = 0.012;SD, p = 0.01)。结论：AHCL系统可能有助于减轻可能干扰实现最佳血糖控制的问题人格特征的影响。E.雷斯米尼：没有。A.V. Cornaghi：没有。V. Turra：没有。E. Zarra：没有。西米诺先生：议长办公室；罗氏、雅培。桑德拉：没有。M. Migazzi：没有。马萨里：没有。B.帕斯基诺：没有。马斯卡德里：没有。S. Madaschi：没有。A. Girelli：顾问；雅培诊断，赛诺菲，罗氏糖尿病护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

935-P: Personality Traits and Glycemic Control in Type 1 Diabetic Patients with Different Insulin Therapies

Introduction and Objective: Glycemic variability is becoming increasingly important in evaluating effectiveness of treatment in patients with type 1 diabetes. Personality traits may impact daily therapeutic decisions, potentially affecting quality of glycemic control. This study aimed to explore potential relationship between personality traits and glycemic control, and to examine differences across various insulin therapies. Methods: Cross-sectional observational study, 130 type 1 diabetic patients (68 females, 62 males, 43.77±12.81 years, BMI 24.95±4.57 kg/m2, disease duration 23.23±12.39 years, HbA1c 7.04±0.92%), divided in three groups: 1. Multiple daily injections (MDI, n=45); 2. Traditional pumps (TP, n=35); 3. Advanced hybrid closed-loop systems (AHCL, n=50). Personality was assessed through the Personality Inventory for DSM-V questionnaire. Kruskal-Wallis test for independent samples was used to compare continuous variables among three groups. Associations between pairs of variables were analyzed using Spearman’s correlation. Results: AHCL group showed higher emotional lability (p=0.042), perseveration (p=0.005), separation insecurity (p=0.007) and distractibility (p=0.021) than MDI and TP group. The pathological trait of emotional lability (above the 75th percentile) was more frequently present in the AHCL (32%, p=0.029) than MDI and TP group. This trait was associated with an increase in TAR>180 (p=0.035) and GMI (p=0.025), a decrease in TBR<70 (p=0.014). However, glycemic control and metrics were significantly better in the AHCL than MDI and TP group (HbA1c, p=0.03; GRI, p<0.001; TIR, p=0.004; TAR>180, p=0.05; TBR<70, p=0.018, TAR>250, p=0.041; CV, p=0.012; SD, p=0.01). Conclusion: AHCL systems may help mitigating the impact of problematic personality traits, that could interfere achieving an optimal glycemic control. Disclosure E. Resmini: None. A.V. Cornaghi: None. V. Turra: None. E. Zarra: None. E. Cimino: Speaker's Bureau; roche, Abbott. M. Sandri: None. M. Migazzi: None. G. Massari: None. B. Pasquino: None. C. Mascadri: None. S. Madaschi: None. A. Girelli: Consultant; Abbott Diagnostics, Sanofi, Roche Diabetes Care.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes 医学-内分泌学与代谢

CiteScore

12.50

自引率

2.60%

发文量

1968

审稿时长

1 months

期刊介绍： Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes. However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.